An investment firm based in the Middle East is a premier investment company with a diverse portfolio spanning multiple asset classes, including real assets and alternative investments. The firm’s vision is to become a leading integrated solutions provider in cell and gene therapy, establishing itself as the first globally trusted partner in precision medicine within the Middle East. The firm focuses on providing research, manufacturing, and a comprehensive range of services related to genomic medicine, targeting local, regional, and international markets. Check sizes vary and are flexible but on average range between USD $5–10M. In alignment with national strategic initiatives, the firm aims to act as a catalyst for developing this vital industry and emphasizes the importance of the private sector in supporting emerging, innovative sectors. The firm aspires to accelerate the delivery of groundbreaking innovations and ensure patient access to treatments for chronic and rare diseases while contributing to the localization of the biotechnology industry and building national expertise to achieve these ambitious goals.
Within therapeutics, the firm is focused on cell and gene therapy in IND, Phase 1, and/or moving into Phase 2. There are several indications of interest, including orphan diseases, oncology, neurology, immunology, cardiovascular diseases, and diabetes. For tech-driven biosciences, the firm is interested in AI-driven platforms for drug discovery and clinical development.
The firm is only interested in companies willing to work toward the goal of bringing biotech innovation to the region through manufacturing and clinical development. A carve-out or partnership in the region is necessary.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment